Filing Flows › Beta Bionics (BBNX) › Q3 2026 › vs Q3 2025
Beta Bionics (BBNX) Q3 2026 vs Q3 2025 (year over year)
Beta Bionics's revenue rose $8.3M (+30%) from $27.3M in Q3 2025 to $35.5M in Q3 2026.
Beta Bionics, Q3 2026: revenue $35.5M (+30% year over year), operating margin -74.9%, net loss $24.4M, operating cash flow −$12.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $35.5M | $27.3M | $8.3M | +30% |
| Other income, net | $2.3M | $2.8M | −$578K | -20% |
| Net loss | $24.4M | $14.2M | $10.1M | +71% |
| Costs & expenses | $62.1M | $44.3M | $17.8M | +40% |
| Operating costs | $62.1M | $44.3M | $17.8M | +40% |
| Cost of revenue | $15.2M | $12.1M | $3.0M | +25% |
| Research & development | $12.0M | $8.2M | $3.8M | +46% |
| Sales & marketing | $25.1M | $16.0M | $9.1M | +57% |
| General & admin | $9.8M | $7.9M | $1.9M | +24% |
| Operating cash sources | $24.4M | $14.2M | $10.1M | +71% |
| Depreciation | $892K | $385K | $507K | +132% |
| Share-based compensation | $6.7M | $4.5M | $2.2M | +50% |
| Working capital & other | $4.5M | $617K | $3.8M | +623% |
| Cash used in operations | $12.3M | $8.7M | $3.6M | +41% |
| Net loss absorbed | $24.4M | $14.2M | $10.1M | +71% |
Questions
How much did Beta Bionics's revenue grow year over year in Q3 2026?
Beta Bionics's revenue rose $8.3M (+30%) from $27.3M in Q3 2025 to $35.5M in Q3 2026.